Johan Wäborg, CEO, Iconovo

Iconovo focuses on commercialization

Iconovo is currently undergoing a strategic reorganization in connection with the company's five inhaler platforms reaching full development. In an interview...

22th of May 2025

Iconovo raises capital and reorganizes

Iconovo is raising capital of SEK 36,6 million and is simultaneously restructuring the organization with the aim of strengthening the commercial focus now...

20th of May 2025
Johan Wäborg, CEO, Iconovo

BioStock Investor Pitch: Iconovo

The subscription period has now begun for Iconovo's rights issue. The issue will finance continued partnership discussions around ICOpre, the development of an intranasal semaglutide product...

16th of May 2025
Lonza

Iconovo and Lonza launch collaboration to strengthen obesity projects

Iconovo enters into a strategic partnership with Lonza to take the next step in the company's obesity project. By contributing...

January 16
Iconovo

Capital injection strengthens Iconovo

Iconovo is raising capital to continue driving its inhalation projects forward. The goal is, among other things, to secure licensing agreements...

November 7
Iconovo

Inhalation specialists Iconovo raises capital

An intranasal obesity treatment under development, a generic challenger to the asthma product Symbicort and talks with potential partners are on the agenda...

November 4
ICOone Nasal

Future obesity treatment: Iconovo invests in intranasal semaglutide

Iconovo has initiated the development of an intranasally inhaled and reformulated version of semaglutide for the treatment of obesity. By...

September 16

BioStock Global Forum 2024

On May 29-30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing...

June 3th, 2024
Full focus on financing and new CEO for Arcede

Full focus on financing and new CEO for Arcede

Preparations for Phase I are largely complete. What Arcede Pharma now needs to solve is financing for upcoming...

22th of May 2024
Iconovo

Iconovo begins development of inhaled obesity treatment

Iconovo has filed a broad patent application for inhaled GLP-1 receptor agonists, which are used for the treatment of obesity and type 2 diabetes....

21th of May 2024
Arcede results

New results confirmed for Arcede Pharma

Preclinical studies at the Università degli studi di Roma Tor Vergata confirm that the drug candidate RCD405 has both airway dilating and anti-inflammatory...

10th of May 2024
Iconovo

Iconovo begins 2024 with orders from leading pharmaceutical companies

Iconovo has received an order from one of the world's ten largest pharmaceutical companies. In addition, the company is strengthening its CDMO business model by...

February 12